This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pot-stocks: Archive
Aurora Cannabis Stock: What Organigram's Buyout Means for Investors
by Sundeep Ganoria
Aurora Cannabis shares surged after Organigram agreed to a C$561 million buyout, but competing bids, deal conditions and shareholder uncertainty remain.
ACBPositive Net Change OGINegative Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Post-Q3 Earnings: Is SNDL Stock a Portfolio Must-Have?
by Sundeep Ganoria
SNDL's Q3 sales beat expectations, but margin pressure and persistent cannabis weakness cloud its recovery. Can buybacks and U.S. expansion turn the tide?
SNDLPositive Net Change TLRYPositive Net Change ACBPositive Net Change
marijuana medical pot-stocks
Should You Buy Curaleaf Stock Amid Its Hostile Bid for Aurora?
by Sundeep Ganoria
CURLF's hostile Aurora bid adds uncertainty as revenues recover, but margin pressure, rising costs and intense competition keep investors cautious.
CURLFNegative Net Change ACBPositive Net Change GTBIFPositive Net Change TSNDFNegative Net Change
marijuana medical pot-stocks
CRON Stock Rises 17% in Three Months: Time to Buy the Dip or Cash Out?
by Sundeep Ganoria
Cronos Group stock climbs 17% in three months on strong revenue growth and margin gains, but rising competition and regulatory risks raise questions about its upside.
CRONNegative Net Change TLRYPositive Net Change VFFPositive Net Change
marijuana medical pot-stocks
TLRY Stock Loses 17% in Three Months: Should You Buy, Hold or Sell?
by Sundeep Ganoria
Tilray's revenues and EBITDA are growing, but weak margins, negative cash flow and competition raise questions about its next move.
TLRYPositive Net Change CGCNegative Net Change ACBPositive Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Cannabis Stock CRLBF Surges 10% in a Month: Time to Buy or Sell?
by Sundeep Ganoria
Cresco's 10% monthly rally reflects stronger revenues, organic growth and margins, but competition and normalization risks cloud the outlook.
CRLBFNegative Net Change ACBPositive Net Change CURLFNegative Net Change VRNOPositive Net Change
marijuana medical pot-stocks
Cannabis Stock VRNO Rises 10% in a Month: Time to Buy, Hold or Sell?
by Sundeep Ganoria
Verano's rally follows strong Q2 results, but margin pressure and wider 2026 losses keep the stock in wait-and-watch mode.
VRNOPositive Net Change ACBPositive Net Change GTBIFPositive Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Cannabis Operator CGC Rises 15% in a Month: Time to Buy, Hold or Sell?
by Sundeep Ganoria
Canopy Growth's cannabis business is showing signs of a turnaround, with revenue growth, improving margins and a narrower EBITDA loss fueling its rally.
CGCNegative Net Change TLRYPositive Net Change ACBPositive Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Should You Buy ACB Stock Amid Curaleaf's Hostile Takeover Attempt?
by Sundeep Ganoria
Aurora Cannabis faces a potential Curaleaf takeover at a 45% premium, but investors must weigh the offer against ACB's standalone prospects.
ACBPositive Net Change TLRYPositive Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Should You Buy, Hold or Sell GTBIF Stock Post Q2 Earnings Release?
by Sundeep Ganoria
Green Thumb tops Q2 earnings and sales estimates, but can regulatory catalysts, buybacks and expansion plans outweigh pricing pressure and fierce competition?
GTBIFPositive Net Change TLRYPositive Net Change TRLVPositive Net Change
marijuana medical pot-stocks